
LFCR Stock Forecast & Price Target
LFCR Analyst Ratings
Bulls say
Lifecore Biomedical is an OUTPERFORM-rated integrated contract development and manufacturing organization (CDMO), with a rapidly increasing percentage of recurring and robust revenue streams from its 30+ ongoing projects (50% commercial, 50% clinical). Due to CEO Paul Josephs' energetic and focused management over the past two years, combined with the company's recent $100 million tech transfer wins, we expect materially expanding capacity utilization, optimized procurement processes, and strong operating margins in 2028 and beyond.
Bears say
Lifecore Biomedical is facing risks in meeting their revenue and earnings estimates according to their recent NDR, with a downward revised price target from $5.50 to $6.00. Although they have spent time with investors to discuss highlights and maintain a constructive long-term outlook, there could still be challenges in achieving the target.
This aggregate rating is based on analysts' research of Lifecore Biomedical Inc and is not a guaranteed prediction by Public.com or investment advice.
LFCR Analyst Forecast & Price Prediction
Start investing in LFCR
Order type
Buy in
Order amount
Est. shares
0 shares